Comparison of the Rate of APRI, Which is an Indirect Indicator of Hepatic Fibrosis, Before and After Treatment in Chronic Hepatitis C Patients with Sustained Viral Response

Introduction: A high rate of viral eradication has been achieved with the use of direct-acting antivirals in the treatment for chronic hepatitis C (CHC). The aspartate aminotransferase to platelet ratio index (APRI) is an easily calculated index and noninvasive approach for the evaluation of hepatic fibrosis in patients who have achieved sustained virologic response (SVR). In this study, we aimed to evaluate the difference between pre- and post-treatment APRI values, one of the indirect markers of fibrosis, in patients with CHC. Materials and Methods: Patients who achieved SVR after they were started on direct-acting antiviral therapy for CHC between June 2016 and December 2018 at the gastroenterology outpatient clinic were retrospectively analyzed. The treatment received and cirrhosis status of the patients were recorded. APRI values calculated before the treatment and 12 weeks after treatment were compared. Results: In total, 87 patients were included in the study. The mean age of the patients was 67 ± 9 years, and 70.1% (n= 61) were female. Twenty-six patients (29.9%) had previously received treatment, 81 (93.1%) had HCV genotype 1, and 53 (60.9%) were noncirrhotic. One patient was coinfected with hepatitis B virus, and one patient had history of liver transplantation. APRI values calculated from serum tests performed before treatment and 12 weeks after treatment were compared. The mean pre- and post-treatment APRI values were 1 (min–max: 0.12–5.35) and 0.4 (0.12–3.48), respectively. There was a statistically significant decrease in the APRI values (p≤ 0.001). Conclusion: There was a significant decrease in the APRI value in patients with CHC who received direct-acting antiviral therapy. A significant improvement in APRI value was observed in patients who achieved SVR.

Medienart:	E-Artikel

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi - 27(2022), 3, Seite 430-435 Zur Gesamtaufnahme - volume:27

Sprache:	Englisch ; Türkisch

Beteiligte Personen:	Süleyman COŞGUN [VerfasserIn] Aydan AKALIN [VerfasserIn]

Links:	doi.org [kostenfrei] doaj.org [kostenfrei] floradergisi.org [kostenfrei] Journal toc [kostenfrei] Journal toc [kostenfrei]

Themen:	Chronic hepatitis c Direct-acting antiviral Infectious and parasitic diseases Microbiology Sustained virologic response

doi:	10.5578/flora.20229706

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	DOAJ02754589X